Actavis offers to guarantee Forest Laboratories' notes for acquisition

By Susanna Moon

Chicago, May 22 - Actavis plc is offering to guarantee three series of notes issued by Forest Laboratories, Inc. in exchange for eliminating registration rights obligations for those notes.

The company is offering to guarantee the $1.05 billion 4 3/8% senior notes due 2019, $750 million 4 7/8% senior notes due 2021 and $1.2 billion 5% senior notes due 2021, according to a press release.

The offer is related to the company's pending acquisition of Forest Laboratories.

The consent solicitations will end at 5 p.m. ET on June 6.

D.F. King & Co., Inc. (212 269-5550, 800 967-4617 or frx@dfking.com) is the information and tabulation agent.

Actavis is a pharmaceutical company with headquarters in Dublin. Forest Laboratories is a New York-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.